M3 Inc.

Japan's largest digital platform for healthcare professionals

Company Overview

M3 Inc. is a Tokyo-based health technology company that operates the largest online platform for healthcare professionals in Japan, with over 300,000 physician members. The company provides clinical decision support, medical marketing, and digital health solutions. M3 has expanded internationally through acquisitions and partnerships, operating in the US, UK, China, and South Korea. It represents a unique model of physician-network-driven health tech innovation.

Sectors

Digital HealthPhysician PlatformMedTech

Primary Markets

JapanUSUKChina

Why This Company Matters

M3 Inc. operates the world's largest online platform for physicians, connecting over 6 million doctors globally, and is a key player in digital clinical trials and medical AI.

Key Focus Areas

Physician PlatformDigital Clinical TrialsMedical AIHealthcare MarketingTelemedicine

Peer Companies

View all

BeiGene

6 signals

China's largest global biotech company focused on innovative oncology medicines

Beijing, China

Biocon

1 signals

India's largest biopharmaceutical company and global biosimilars leader

Bangalore, India

Celltrion

2 signals

South Korea's leading biosimilar manufacturer challenging global pharma giants

Incheon, South Korea

Daiichi Sankyo

0 signals

Japanese pharmaceutical giant leading in antibody-drug conjugates (ADCs)

Tokyo, Japan

Doctor Anywhere

0 signals

Southeast Asia's leading omnichannel healthcare platform

Singapore

Halodoc

2 signals

Indonesia's leading telehealth and health-tech platform

Jakarta, Indonesia

Signal Activity

0This Month

0Last 30 Days

2Total

Signal Timeline

2 total

November 2025

EarningsCanonicalNov 12

M3 Inc. Reports FY2025 Q3 Consolidated Financial Results

M3 Inc. has released its consolidated financial results for the third quarter of fiscal year 2025. The report details the company's financial performance, including revenue, profit, and other key financial indicators. Investors and analysts will review these figures to assess M3's ongoing business trajectory and profitability. The results provide insights into the company's operational efficiency and market position during the specified period.

August 2024

AcquisitionCanonicalAug 6

M3's VIDAL Group Acquires GPR for Renal Failure Support in France

M3 Inc.'s VIDAL Group has acquired GPR, a company specializing in prescription support tools for renal failure patients in France. This acquisition aims to enhance M3's healthcare offerings by integrating GPR's technology and patient support capabilities into its existing services. The move is expected to strengthen M3's position in the French pharmaceutical and patient support market, providing a more comprehensive solution for chronic kidney disease management.

Get M3 Inc. signal updates

Get notified when new signals are published for this company.

Explore More Industries

All Industries

AI & Frontier Intelligence49 signals Fintech & Digital Finance28 signals Mobility, EV & Autonomous Systems44 signals Energy, Climate & Industrial Transition34 signals